Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

Efficacy and Safety of Leuprorelin Acetate Every-3-months Depot Plus an Aromatase Inhibitor or Tamoxifen in Premenopausal Women With Hormone Receptor-positive Breast Cancer: a Clinical Prospective Observational Study

Leuprorelin, a LHRH agonist, acts as a potent inhibitor of gonadotropin secretion and is commonly used for the treatment of hormone-responsive prostate cancer, premenopausal HR+ breast cancer, endometriosis and uterine fibroids. It is currently available in 1M, 3M, 6M for subcutaneous administration. Initially administration would stimulate an increase in LH and FSH, causing a transient increase of E2 in 2-4 weeks. Continuous administration results in a subsequent decrease in E2 levels, as a result of decreased levels of luteinizing LH and FSH. After stopping injection, ovarian function could gradually recover. Adverse events related to leuprorelin include flushing, mood swings and urogenital symptoms.

At present, the treatment of premenopausal breast cancer mainly includes 1M and 3M GnRHa. Leuprorelin 11.25mg dosage form is currently the only 3M GnRHa in China that has gotten breast cancer indications. The use of 3M GnRHa could improve patients' compliance and reduce injection discomfort. However, previous studies about GnRHa alone or in combination with TAM or AIs usually used 1M GnRHa. There have been few studies reporting the suppression effects of E2 levels and clinical outcome with leuprorelin 3M in combination with TAM or AIs.

Study Overview

• Status: Not yet recruiting
• Conditions: Hormone Receptor-positive Breast Cancer
• Intervention / Treatment: Drug: AI or TAM

Detailed Description

Background:

There are some differences in the age of onset of breast cancer, histopathological types, and treatment methods between Asians and non-Asians. Incidence peaks at age 40-50 in Asian women, with more than half of premenopausal patients, but 65-70 years in US women, most of which are postmenopausal[1]. Besides, compared with Americans, Asian women younger than 50 have a higher prevalence of luminal A breast cancer and less basal-like subtype. Therefore, the application of OFS has always been the focus for the treatment of premenopausal women with HR+ breast cancer in Asia.

OFS therapy includes oophorectomy, ovarian radiation, and the use of GnRHa. Several studies have shown that the use of GnRHa in premenopausal women can achieve similar efficacy to oophorectomy and ovarian radiation therapy. As GnRHa has the advantages of non-invasiveness and reversibility, it has gradually replaced oophorectomy and ovarian radiation, and has become the main method of OFS in premenopausal women with HR+ breast cancer. Meanwhile, GnRHa in combination with TAM or AIs is increasingly used for premenopausal HR+ breast cancer patients. Previous studies have revealed that GnRHa alone or in combination with TAM or AIs has shown effective estrogen suppression and certain survival benefits for most patients with breast cancer. In addition, the 5-year follow-up results of the TEXT / SOFT study in 2014 showed that compared with OFS + TAM, OFS + AI treatment significantly improved DFS, prolonged cancer-free survival time and distant recurrence-free metastasis[8, 9]. The 9-year follow-up results of the TEXT / SOFT study in 2019 indicated that OFS + AI versus OFS + TAM or TAM single drugs, years of distant recurrence risk in patients with high risk of recurrence have an absolute benefit rate of 10-15 %, Intermediate risk is 4-5%, low-risk benefit is not obvious. In 2019, the ABCCG reviewed ESO-ESMO and St. Gallen's treatment recommendations for HR+/ Her-2 negative breast cancer in premenopausal women, discussed controversial issues and pointed out that patients with low recurrence risk can be treated with TAM alone. For patients with high risk of recurrence, chemotherapy + OFS + AI should be given. It indicates that not all premenopausal HR+ patients with early breast cancer need auxiliary OFS, and more clinical trials on OFSin premenopausal HR + patients are necessary and worthwhile.

Leuprorelin, a LHRH agonist, acts as a potent inhibitor of gonadotropin secretion and is commonly used for the treatment of hormone-responsive prostate cancer, premenopausal HR+ breast cancer, endometriosis and uterine fibroids. It is currently available in 1M, 3M, 6M for subcutaneous administration. Initially administration would stimulate an increase in LH and FSH, causing a transient increase of E2 in 2-4 weeks. Continuous administration results in a subsequent decrease in E2 levels, as a result of decreased levels of luteinizing LH and FSH. After stopping injection, ovarian function could gradually recover. Adverse events related to leuprorelin include flushing, mood swings and urogenital symptoms.

At present, the treatment of premenopausal breast cancer mainly includes 1M and 3M GnRHa. Leuprorelin 11.25mg dosage form is currently the only 3M GnRHa in China that has gotten breast cancer indications. The use of 3M GnRHa could improve patients' compliance and reduce injection discomfort. However, previous studies about GnRHa alone or in combination with TAM or AIs usually used 1M GnRHa. There have been few studies reporting the suppression effects of E2 levels and clinical outcome with leuprorelin 3M in combination with TAM or AIs.

To further investigate the suppression effects of E2 levels of 3M GnRHa, we conducted a single-arm, prospective clinical observational study evaluating the efficacy and safety of adjuvant therapy with leuprorelin 3M in combination with TAM or AIs in premenopausal HR+ breast cancer.

• Study Type: Observational
• Enrollment (Anticipated): 120

Contacts and Locations

• Study Contact: Name: Yudong Li, MD; Phone Number: 020-34071156; Email: 910870698@qq.com
• Study Contact Backup: Name: Jingna Lin, MD; Phone Number: 18819430558; Email: 229320178@qq.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Premenopausal patients with histologically confirmed hormone receptor-positive breast cancer

Description

Inclusion Criteria:

1. age≥18 years;
2. Tumor that expressed ER or progesterone receptor in at least 10% of the cells, as assessed by immunohistochemical testing
3. T1 to T3, any N, and M0, according to the TNM classification
4. Any type of breast surgical procedure
5. Any type of preoperative and/or postoperative adjuvant chemotherapy prior to enrollment
6. Capable of receiving the study drug within 12 weeks after surgery or after postoperative chemotherapy completion prior to enrollment
7. Eastern Cooperative Oncology Group performance status of Grade 0 or 1

Exclusion Criteria:

1. Bilateral oophorectomy or ovarian irradiation
2. No use of other OFS drugs

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
leuprorelin 3M plus AIs; leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year AIs: anastrozole 1mg /letrozole 2.5mg/exemestane 25mg daily for 1 year	Drug: AI or TAM; This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.
leuprorelin 3M plus TAM; leuprorelin 3M: 11.25 mg subcutaneous administration every 3 months for 1 year TAM: daily for 1 year	Drug: AI or TAM; This is an observational study, the researcher will describe the ratio of E2 control between leuprorelin plus TAM or leuprorelin plus AIs patients based on the actual clinical use.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the suppression proportion of serum estradiol (E2)	The suppression proportion of serum estradiol (E2) to the menopausal level (E2≤30 pg/mL) at different time points (4, 12, 24, 36 and 48 weeks) during the first year for leuprorelin 3M depot plus TAM or AIs.	March,2023

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of Life (QoL)	To evaluate the Quality of Life (QoL) of Patient who receive Leu 3M depot for OFS treatment evaluated by FACT-B and FACT-ES questionnaire.	March,2023
Adverse events(AEs)	To observe the incidence of adverse events(AEs).	March,2023

Collaborators and Investigators

• Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
• Investigators: Principal Investigator: Qiang Liu, MD, Sunyat-sen Memorial Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): May 1, 2021
• Primary Completion (Anticipated): May 1, 2023
• Study Completion (Anticipated): September 1, 2023

Study Registration Dates

• First Submitted: May 17, 2021
• First Submitted That Met QC Criteria: May 17, 2021
• First Posted (Actual): May 18, 2021

Study Record Updates

• Last Update Posted (Actual): May 18, 2021
• Last Update Submitted That Met QC Criteria: May 17, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: SunYatsenU2H-LQ5

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No